Exploration of epithelial-mesenchymal transition-related lncRNA signature and drug sensitivity in breast cancer

被引:6
作者
Li, Chengxin [1 ]
Zheng, Lewei [1 ]
Xu, Gaoran [1 ]
Yuan, Qianqian [1 ]
Di, Ziyang [2 ,3 ]
Yang, Yalong [1 ]
Dong, Xingxing [1 ]
Hou, Jinxuan [1 ]
Wu, Gaosong [1 ]
机构
[1] Wuhan Univ, Zhongnan Hosp, Dept Thyroid & Breast Surg, Wuhan, Peoples R China
[2] Wuhan Univ, Zhongnan Hosp, Dept Gastrointestinal Surg, Wuhan, Peoples R China
[3] Wuhan Univ, Zhongnan Hosp, Dept Gastr & Colorectal Surg Oncol, Wuhan, Peoples R China
关键词
epithelial-mesenchymal transition; breast cancer; long non-coding RNA; prognostic model; drug sensitivity; MOLECULAR-MECHANISMS; GASTRIC-CANCER; METASTASIS; EMT; DOXORUBICIN; INHIBITION; RESISTANCE; CELLS;
D O I
10.3389/fendo.2023.1154741
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundBreast cancer (BRCA) has become the most diagnosed cancer worldwide for female and seriously endanger female health. The epithelial-mesenchymal transition (EMT) process is associated with metastasis and drug resistance in BRCA patients. However, the prognostic value of EMT-related lncRNA in BRCA still needs to be revealed. The aim of this study is to construct an EMT-related lncRNA (ERL) signature with accuracy predictive ability for the prognosis of BRCA patients. MethodsRNA-seq expression data and Clinical characteristics obtained from the TCGA (The Cancer Genome Atlas) were used in the study. First, we identified the EMT-related lncRNA by the Pearson correlation analysis. An EMT-related lncRNAs prognostic risk signature was constructed using univariate Cox regression and Lasso-penalized Cox regression analyses. The model's performance was validated using Kaplan-Meier (KM) survival analysis, ROC curve and C-index. Finally, a nomogram was constructed for clinical practice in evaluating the patients with BRCA and validated by calibration curve and decision curve analysis (DCA). We also evaluated the drug sensitivity of signature lncRNA and the tumor immune cell infiltration in breast cancer. ResultsWe constructed a 10-lncRNA risk score signature based on the lncRNAs associated with the EMT process. We could assign BRCA patients to the high- and low-risk group according to the median risk score. The prognostic risk signature showed excellent accuracy and demonstrated sufficient independence from other clinical characteristics. The immune cell infiltration analysis showed that the prognostic risk signature was related to the infiltration of the immune cell subtype. Drug sensitivity analysis proved ERLs signature could effectively predict the sensitivity of patients to common chemotherapy drugs in BRCA and provide guidance for chemotherapy drugs for high-risk and low-risk patients. ConclusionOur ERL signature and nomogram have excellent prognostic value and could become reliable tools for clinical guidance.
引用
收藏
页数:13
相关论文
共 42 条
[1]   AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patients [J].
Bottai G. ;
Raschioni C. ;
Székely B. ;
Di Tommaso L. ;
Szász A.M. ;
Losurdo A. ;
Győrffy B. ;
Ács B. ;
Torrisi R. ;
Karachaliou N. ;
Tőkés T. ;
Caruso M. ;
Kulka J. ;
Roncalli M. ;
Santoro A. ;
Mantovani A. ;
Rosell R. ;
Reis-Filho J.S. ;
Santarpia L. .
npj Breast Cancer, 2 (1)
[2]   Triple-negative breast cancer: disease entity or title of convenience? [J].
Carey, Lisa ;
Winer, Eric ;
Viale, Giuseppe ;
Cameron, David ;
Gianni, Luca .
NATURE REVIEWS CLINICAL ONCOLOGY, 2010, 7 (12) :683-692
[3]   Necroptosis-related lncRNA to establish novel prognostic signature and predict the immunotherapy response in breast cancer [J].
Chen, Fangyue ;
Yang, Jun ;
Fang, Min ;
Wu, Yanmei ;
Su, Dongwei ;
Sheng, Yuan .
JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2022, 36 (04)
[4]   Endocrine resistance in breast cancer - An overview and update [J].
Clarke, Robert ;
Tyson, John J. ;
Dixon, J. Michael .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2015, 418 :220-234
[5]   RETRACTED: LncRNA DLX6-AS1 Contributes to Epithelial-Mesenchymal Transition and Cisplatin Resistance in Triple-negative Breast Cancer via Modulating Mir-199b-5p/Paxillin Axis (Retracted article. See vol. 33, 2024) [J].
Du, Chuang ;
Wang, Yan ;
Zhang, Yingying ;
Zhang, Jianhua ;
Zhang, Linfeng ;
Li, Jingruo .
CELL TRANSPLANTATION, 2020, 29
[6]   miR-137 alleviates doxorubicin resistance in breast cancer through inhibition of epithelial-mesenchymal transition by targeting DUSP4 [J].
Du, Feiya ;
Yu, Ling ;
Wu, Ying ;
Wang, Shuqian ;
Yao, Jia ;
Zheng, Xiaoxiao ;
Xie, Shangzhi ;
Zhang, Shufeng ;
Lu, Xuemei ;
Liu, Yu ;
Chen, Wei .
CELL DEATH & DISEASE, 2019, 10 (12)
[7]  
Francou A, 2020, ANNU REV CANC BIOL, V4, P197, DOI [10.1146/annurev-cancerbio-030419-055425, 10.1146/annurev-cancerbio-030518-055425]
[8]   The mechanism between epithelial mesenchymal transition in breast cancer and hypoxia microenvironment [J].
Gao, Tong ;
Li, Jia-zhi ;
Lu, Ying ;
Zhang, Chun-ying ;
Li, Qing ;
Mao, Jun ;
Li, Lian-hong .
BIOMEDICINE & PHARMACOTHERAPY, 2016, 80 :393-405
[9]   Cancer-Associated Stemness and Epithelial-to-Mesenchymal Transition Signatures Related to Breast Invasive Carcinoma Prognostic [J].
Groza, Iulia-Monica ;
Braicu, Cornelia ;
Jurj, Ancuta ;
Zanoaga, Oana ;
Lajos, Raduly ;
Chiroi, Paul ;
Cojocneanu, Roxana ;
Paun, Diana ;
Irimie, Alexandru ;
Korban, Schuyler S. ;
Achimas-Cadariu, Patriciu ;
Berindan-Neagoe, Ioana .
CANCERS, 2020, 12 (10) :1-21
[10]  
Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO